Additional 4-week capecitabine during the resting periods after 6-week neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: long-term oncologic outcomes
Annals of Surgical Treatment and Research
;
: 306-311, 2018.
Article
in English
| WPRIM
| ID: wpr-715547
ABSTRACT
PURPOSE:
The aim of this study was to evaluate the long-term outcome of additional 4-week chemotherapy with capecitabine during the resting periods following a 6-week neoadjuvant chemoradiotherapy (NCRT) regimen, in patients with locally advanced rectal cancer.METHODS:
Radiotherapy was delivered to the whole pelvis at a total dose of 50.4 Gy for 6 weeks. Oral capecitabine was administered at a dose of 825 mg/m2 twice daily for 10 weeks. Surgery was performed 2–4 weeks following the completion of chemotherapy.RESULTS:
Between January 2010 and September 2011, 41 patients completed the scheduled neoadjuvant therapy and surgery. The pathologic complete response rate, 5-year overall survival, and 5-year disease-free survival rates were 22%, 85.4%, and 78.0%, respectively. The 5-year systemic recurrence and 5-year local recurrence rates were 22% and 0%, respectively.CONCLUSION:
Additional 4-week chemotherapy with capecitabine, during the resting periods following a 6-week NCRT regimen, has favorable long-term oncologic outcomes. Further randomized controlled trials are however necessary to evaluate if substantial improvement in local control is achieved with this additional chemotherapy modality for locally advanced rectal cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pelvis
/
Prognosis
/
Radiotherapy
/
Rectal Neoplasms
/
Recurrence
/
Disease-Free Survival
/
Neoadjuvant Therapy
/
Drug Therapy
/
Chemoradiotherapy
/
Capecitabine
Type of study:
Controlled clinical trial
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Annals of Surgical Treatment and Research
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS